Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135903 | 0.92 | P2RX7 (0.51) | P2RX7CNR2KDM4EALDH1A1HPGD | |
| SCHEMBL4144738 | 0.88 | P2RX7 (0.51) | P2RX7KDM4EALDH1A1HPGDEPHX2 | |
| SCHEMBL4139008 | 0.88 | P2RX7 (0.60) | P2RX7PDPK1 | |
| SCHEMBL4132630 | 0.88 | P2RX7 (0.53) | P2RX7CNR2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4157822 | 0.87 | P2RX7 (0.49) | P2RX7CNR2KDM4EALDH1A1 | |
| SCHEMBL4137660 | 0.87 | P2RX7 (0.50) | P2RX7KDM4EALDH1A1HPGDEPHX2 | |
| SCHEMBL4991116 | 0.86 | P2RX7 (0.47) | P2RX7KDM4EALDH1A1HPGD | |
| SCHEMBL4150372 | 0.86 | P2RX7 (0.47) | P2RX7KDM4EALDH1A1L3MBTL1HPGD | |
| SCHEMBL4133219 | 0.86 | P2RX7 (0.48) | P2RX7CNR2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4147936 | 0.86 | P2RX7 (0.51) | P2RX7CNR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | claimed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | claimed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | claimed |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885PDPK1 504/4885CNR2 42/4885 |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885PDPK1 504/4885CNR2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.